drugset / Trial / NCT03415477

Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts

NCT03415477

Phase 1/2 Completed 6 enrolled Peking University People's Hospital
NaSingle-groupOpen-labelTreatment

Summary

The efficacy of traditional therapeutic approaches for aneurysmal bone cysts (ABC), such as surgery, embolization, sclerotherapy and radiotherapy, are often compromised for lesions in axial skeletons and adolescents complicated with pathological fracture. Therefore, denosumab, a new drug that has been successfully used in giant cell tumor of bone but has seldom used in ABC, was used to treat ABC in this trial.

Timeline

Start
2014-01-01
Primary completion
2016-12-31
Completion
2017-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody 120 mg Subcutaneous

Indications